REGISTER

What to Expect:

Daiichi Sankyo is excited to host a special event to celebrate innovation and announce the recipient of the inaugural Daiichi Sankyo Golden Tickets. As a Platinum sponsor of LabCentral, Daiichi Sankyo is committed to supporting groundbreaking life science and biotech startups. This gathering will bring together entrepreneurs, scientists, and industry leaders for an evening of networking, inspiration, and collaboration. Attendees will have the opportunity to hear from Daiichi Sankyo’s expert team, learn more about advancements in oncology and specialty medicine, and witness the live announcement of the Golden Ticket winners.

The two recipients will each receive a $50,000 credit toward space and services at LabCentral’s flagship site, along with access to Daiichi Sankyo’s industry-leading expertise. Join us for an evening dedicated to fostering the next generation of biotech breakthroughs!

Agenda:

Finalists:

Noara Therapeutics

Noara Therapeutics pioneers the next generation of RNA-based therapeutics with cutting-edge RNA technology. Their proprietary platform delivers unmatched stability, immunosilence, and therapeutic potential, addressing challenges in chronic diseases by protein replacement therapies to redefine the future of RNA medicine.

Sendatu Therapeutics

Sendatu Therapeutics is developing advanced AAV-based gene delivery systems using a novel, AI-driven approach. Their technology designs tailored peptide libraries which will accelerate development, lowers costs, and improve the clinical success of AAV-based therapies.

Matrisome Bio

Matrisome Bio is developing tools to deliver targeted therapies to the extracellular matrix (non-cellular components) of disease tissues such as tumors and fibrotic lesions in order to convert it from a barrier to a drug depot.

Tiago Therapeutics

Tiago Therapeutics leverages the non-viral delivery of DNA-based payloads to enable exquisite cell type-selective gene expression for the treatment of diseases of high unmet need.

 

Vrata Therapeutics

Vrata Therapeutics is developing a cell-penetrating antibody capable of delivering nucleic acid cargo directly to the cytoplasm of cells. This antibody allows avoidance of the endosomal escape problem, which severely limits the amount of nucleic acid therapeutic that actually gets to the site of action in the cell.

Transit Therapeutics

The stealth-mode company Transit Therapeutics is applying protein-free trans-splicing of mRNA to create therapeutic treatments for genetic diseases, addressing both permanent and transient applications. The scientific co-founders are from reputable institutions such as Harvard/MIT and UC Berkeley. 

Judging Panel:

REGISTER